Inhibrx Inc

Inhibrx — Investor Presentation (October 2021)

29 slides from Inhibrx's investor presentation, October 2021

  1. Slide 1: Innovation Driven, Outcomes Focused

    Innovation Driven Outcomes Focused October 2021

  2. Slide 2: Presentation disclaimer

    Presentation disclaimer This presentation contains forward-looking statements. In some cases, you can could differ materially from the plans, intentions and expectations disclosed identify forward-looking statements by the words “will,” “expect,” “intend,” in the forward-looking statements the Compa

  3. Slide 3: Inhibrx at a glance

    Inhibrx at a glance VALIDATION FROM INDUSTRY LEADING PARTNERS + Experienced leadership team All platforms and programs + Proven innovation and execution developed in-house with strong patent protection + Ability to precision engineer to specific target biology + Smaller than conventional antibodies

  4. Slide 4: Four differentiated clinical programs

    Four differentiated clinical programs Rare diseases Oncology Cell death pathway Immuno-oncology INBRX-101 INBRX-109 INBRX-106 INBRX-105 AAT-Fc fusion protein Tetravalent DR5 agonist Hexavalent OX40 agonist PD-L1 x 4-1BB tetravalent + Potential for first meaningful + Single agent activity + Potential

  5. Slide 5: Why invest in Inhibrx?

    Why invest in Inhibrx? KEY FINANCIAL HIGHLIGHTS* $125.7M Cash Four differentiated clinical Potential to reach programs with value-creating financial sustainability readouts in 2H 2021/2022 with minimal dilution $20-25M Average per Qtr burn rate 37.8M Common stock outstanding Backed by solid institut

  6. Slide 6: INBRX-101

    AAT INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein Fc

  7. Slide 7: Alpha-1 antitrypsin deficiency (AATD)

    Alpha-1 antitrypsin deficiency (AATD) Disease overview ⁺ AATD is an inherited orphan respiratory disease characterized by deficient levels of alpha-1 antitrypsin (AAT) causing loss of lung function and decreased life expectancy ⁺ A small percentage of patients also develop liver disease Current stan

  8. Slide 8: Potential advantages of recombinant AAT Fc-fusion protein INBRX-101

    Potential advantages of recombinant AAT Fc-fusion protein INBRX-101 Potential advantages of INBRX-101 Potential to extend Goal is to maintain patients in the normal Recombinant manufacturing the dosing interval from serum range of AAT and to normalize provides unlimited supply weekly to monthly the

  9. Slide 9: Competitive comparison

    Competitive comparison 100% Applicable to all patients THERAPIES STATUS 15% Applicable to ~15% of patients with liver issues Aralast THERAPIES STATUS Glassia ARO-AAT Phase 2 Approved Plasma-Derived AAT Prolastin-C DCR-A1AT Phase 2 Zemaira Inhaled AAT Phase 2 Oral Neutrophil Alvelestat Phase 2 Elasta

  10. Slide 10: INBRX-101 Initial results from Phase 1, Part 1

    INBRX-101 - Initial results from Phase 1, Part 1 PART 1 Key functional AAT levels by dose Single ascending 60 dose escalation (SAD) Complete Functional AAT levels (μM) N=24 40 Baseline AAT Max AAT N= 6 10 mg/kg Day 21 AAT N= 6 40 mg/kg 20 N= 6 80 mg/kg N= 6 120 mg/kg 0 10 40 80 120 INBRX-101 single

  11. Slide 11: INBRX-101 Initial results from Phase 1, Part 2

    INBRX-101 - Initial results from Phase 1, Part 2 - 40 mg/kg PART 2 Multiple ascending INBRX-101 Initial Results - 40 mg/kg (Q3W) dose escalation (MAD) 40 N=18 Functional AAT levels (μM) 30 N= 6 40 mg/kg Complete 20 N= 6 80 mg/kg* 10 N= 6 120 mg/kg* Initiated * bronchoalveolar lavage 0 0 21 42 63 Tim

  12. Slide 12: INBRX-109

    INBRX-109 Tetravalent DR5 Agonist

  13. Slide 13: Tetravalent DR5 agonist

    Tetravalent DR5 agonist DR5: sdAb DR5: sdAb + Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) DR5: sdAb DR5: sdAb + DR5 activation naturally eliminates damaged and neoplastic cells Fc: effector function disabled 105 kDa 13

  14. Slide 14: INBRX-109 is a best-in-class DR5 agonist

    INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) STATUS INBRX-109 Tetravalent 105 Phase II TAS-266 Tetravalent 60 Discontinued1 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 Phase I GEN10292 Dodecavalent 150 ka (2x mAbs) Phase I IGM-8444 Decavalent3 ~950 Phase I Dulanermin

  15. Slide 15: Fast to market opportunity

    Fast to market opportunity Chondrosarcoma PFS from placebo-controlled studies Incidence rate of ~1 in 200,000 persons per year Therapeutic IPI-926 (HH) Control arm Placebo Subject number 100 (2:1) Placebo arm PFS 2.9 months ~1,400 cases per year Therapeutic Regorafenib Control arm Placebo Subject nu

  16. Slide 16: INBRX-109 preliminary Phase 1 data in chondrosarcoma

    INBRX-109 preliminary Phase 1 data in unresectable or metastatic conventional chondrosarcoma Best Response 3mo 4mo 6mo 9mo 12mo SD (-20%) 62wks ► SD (-7%) 62wks PD SD (-11%) 54wks ► PR (-60%) PD SD (-13%) PD SD (+4%) ► PR (-32%) PD SD (-4%) ** SD (+5%) PD SD (+3%) * SD (-3%) * SD (-4%) * SD (+6%) PD

  17. Slide 17: INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma

    INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma Randomization INBRX-109 Placebo Conventional chondrosarcoma, grade 2 and 3, unresectable or metastatic N=134* N= 67 * Stratification 3 mg/kg every Until PD or toxicity by line of therapy & Grade three weeks with cross-over Initia

  18. Slide 18: Preliminary Phase 1 data-malignant pleural mesothelioma, epithelioid subtype

    Preliminary Phase 1 data-malignant pleural mesothelioma, epithelioid subtype Best Response 3mo 4mo 6mo 9mo PART 3 SD (-24%) * SD (-17%) Combination SD (-12%) study PR (-100%) SD (-22%) Mesothelioma with SD (-20%) N=20 Cis-/Carboplatin sd (-12%) & Pemetrexed SD (-5%) SD (-2%) SD (+9%) H1 2022 SD (+13

  19. Slide 19: INBRX-109 on the horizon

    INBRX-109 on the horizon PART 3 FUTURE POTENTIAL OPPORTUNITIES Combination studies Solid tumors + IAP antagonists Pancreatic adenocarcinoma Hematologic tumors N=20 2nd line with FOLFIRI Ongoing + Bcl-2 inhibitors Ewing sarcoma NSCLC N=20 with Irinotecan + various combo agents Initiated Gastric and c

  20. Slide 20: INBRX-106

    INBRX-106 Hexavalent OX40 Agonist

  21. Slide 21: Hexavalent OX40 agonist

    Hexavalent OX40 agonist OX40: sdAb OX40: sdAb OX40 is a co-stimulatory receptor on activated T-cells: T T + Provides co-stimulation to activated T-cells OX40: sdAb OX40: sdAb + Reverses regulatory T-cell induced T T immune suppression T sdAb OX40: OX40: sdAb + Enhances T-cell functionality T T + Add

  22. Slide 22: INBRX-106 is a best-in-class OX40 agonist

    INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hex- IgG1 N Ph 1 (2019) MOXR-0916 Discontinued GSK-3174998 Ph 1 (MM, 2019) BMS-986178 Ph 1 (2016) INCAGN-1949 Bi- IgG1 Y Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Discont

  23. Slide 23: INBRX-106 Phase 1 trial design

    INBRX-106 Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Single agent Complete Single agent Ongoing Dose escalation Ongoing Dose expansion Planned dose escalation dose expansion with Keytruda™ with Keytruda™ N=20 N= 24 N= 13 N=80 Dose optimization study No pre-screening, all-comers N=20 PD-L1+NSCL

  24. Slide 24: INBRX-105

    INBRX-105 PD-L1 x 4-1BB Multispecific

  25. Slide 25: PD-L1 x 4-1BB multispecific

    PD-L1 x 4-1BB multispecific PD-L1: sdAb PD-L1: sdAb + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune 4-1BB: sdAb 4-1BB: sdAb cells, 4-1BB signaling promotes prolonged T-cell survival memory formation + Constitutive

  26. Slide 26: INBRX-105 is a best-in-class 4-1BB agonist

    INBRX-105 is a best-in-class 4-1BB agonist PD-L1 x 4-1BB Bispecifics CANDIDATE FORMAT 4-1BBL BLOCKING STATUS INBRX-105 Bivalent/Bivalent No Phase I Gen-1064 Monovalent/Monovalent n/a Phase II MCLA-145 Monovalent/Monovalent Yes Phase I FS222 Bivalent/Bivalent n/a Phase I PRS-343 Bivalent/Bivalent No

  27. Slide 27: INBRX-105 Phase 1 trial design

    INBRX-105 Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Single agent Complete Single agent Ongoing Dose escalation Initiated Dose expansion Planned dose escalation dose expansion with Keytruda™ with Keytruda™ N=32 N= 32 N= 12 N=80 Single agent: PD-L1+ Basket No pre-screening, all-comers N=20 PD-L

  28. Slide 28: Near term expected clinical milestones

    Near term expected clinical milestones INBRX-105 INBRX-109 INBRX-109 INBRX-105 (DR5) Initial pancreatic (DR5) Ewing (PD-L1 x 41BB) (PD-L1 x 41BB) and mesothelioma sarcoma Keytruda dose Keytruda dose combination combination expansion escalation data study data study data cohort data Q4 2021 H1 2022 H

  29. Slide 29: 11025 N. Torrey Pines Rd, La Jolla, CA

    11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com

Inhibrx — Investor Presentation (October 2021) on 6ix